Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

Recent Insights into the HIV/AIDS Pandemic.

Becerra JC, Bildstein LS, Gach JS.

Microb Cell. 2016 Sep 5;3(9):451-475. doi: 10.15698/mic2016.09.529. Review.

2.
3.

Editorial: Paradigm Changes are Required in HIV Vaccine Research.

Van Regenmortel MH.

Front Immunol. 2015 Jun 23;6:326. doi: 10.3389/fimmu.2015.00326. eCollection 2015. No abstract available.

5.

Eliciting neutralizing antibodies with gp120 outer domain constructs based on M-group consensus sequence.

Qin Y, Banasik M, Kim S, Penn-Nicholson A, Habte HH, LaBranche C, Montefiori DC, Wang C, Cho MW.

Virology. 2014 Aug;462-463:363-76. doi: 10.1016/j.virol.2014.06.006.

6.

Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike.

Scharf L, Scheid JF, Lee JH, West AP Jr, Chen C, Gao H, Gnanapragasam PN, Mares R, Seaman MS, Ward AB, Nussenzweig MC, Bjorkman PJ.

Cell Rep. 2014 May 8;7(3):785-95. doi: 10.1016/j.celrep.2014.04.001. Epub 2014 Apr 24.

7.

Improvement of antibody responses by HIV envelope DNA and protein co-immunization.

Pissani F, Malherbe DC, Schuman JT, Robins H, Park BS, Krebs SJ, Barnett SW, Haigwood NL.

Vaccine. 2014 Jan 16;32(4):507-13. doi: 10.1016/j.vaccine.2013.11.022. Epub 2013 Nov 23.

8.

Adherence to Antiretroviral Therapy for the Success of Emerging Interventions to Prevent HIV Transmission: A Wake up Call.

Nachega JB, Uthman OA, Mills EJ, Quinn TC.

J AIDS Clin Res. 2013 Oct 22;2012(Suppl 4). pii: 007.

9.

Catching HIV 'in the act' with 3D electron microscopy.

Earl LA, Lifson JD, Subramaniam S.

Trends Microbiol. 2013 Aug;21(8):397-404. doi: 10.1016/j.tim.2013.06.004. Epub 2013 Jul 11. Review.

10.

Immune focusing and enhanced neutralization induced by HIV-1 gp140 chemical cross-linking.

Schiffner T, Kong L, Duncan CJ, Back JW, Benschop JJ, Shen X, Huang PS, Stewart-Jones GB, DeStefano J, Seaman MS, Tomaras GD, Montefiori DC, Schief WR, Sattentau QJ.

J Virol. 2013 Sep;87(18):10163-72. doi: 10.1128/JVI.01161-13. Epub 2013 Jul 10.

11.

Structural basis for HIV-1 gp120 recognition by a germ-line version of a broadly neutralizing antibody.

Scharf L, West AP Jr, Gao H, Lee T, Scheid JF, Nussenzweig MC, Bjorkman PJ, Diskin R.

Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):6049-54. doi: 10.1073/pnas.1303682110. Epub 2013 Mar 22.

12.

Viral escape from neutralizing antibodies in early subtype A HIV-1 infection drives an increase in autologous neutralization breadth.

Murphy MK, Yue L, Pan R, Boliar S, Sethi A, Tian J, Pfafferot K, Karita E, Allen SA, Cormier E, Goepfert PA, Borrow P, Robinson JE, Gnanakaran S, Hunter E, Kong XP, Derdeyn CA.

PLoS Pathog. 2013 Feb;9(2):e1003173. doi: 10.1371/journal.ppat.1003173. Epub 2013 Feb 28.

13.

Designing tomorrow's vaccines.

Nabel GJ.

N Engl J Med. 2013 Feb 7;368(6):551-60. doi: 10.1056/NEJMra1204186. Review. No abstract available.

14.

Rational design of vaccines for AIDS and influenza.

Nabel GJ.

Trans Am Clin Climatol Assoc. 2012;123:9-15; discussion 15-6.

15.

Antigenicity and Immunogenicity in HIV-1 Antibody-Based Vaccine Design.

Kong L, Sattentau QJ.

J AIDS Clin Res. 2012;S8:3. Epub 2012 Mar 22.

16.

Innate immune sensing of HIV-1 by dendritic cells.

Luban J.

Cell Host Microbe. 2012 Oct 18;12(4):408-18. doi: 10.1016/j.chom.2012.10.002. Review.

17.

A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults.

Keefer MC, Gilmour J, Hayes P, Gill D, Kopycinski J, Cheeseman H, Cashin-Cox M, Naarding M, Clark L, Fernandez N, Bunce CA, Hay CM, Welsh S, Komaroff W, Hachaambwa L, Tarragona-Fiol T, Sayeed E, Zachariah D, Ackland J, Loughran K, Barin B, Cormier E, Cox JH, Fast P, Excler JL.

PLoS One. 2012;7(8):e41936. doi: 10.1371/journal.pone.0041936. Epub 2012 Aug 3.

18.

Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 agonist, promotes potent systemic and mucosal responses to intranasal immunization with HIVgp140.

Arias MA, Van Roey GA, Tregoning JS, Moutaftsi M, Coler RN, Windish HP, Reed SG, Carter D, Shattock RJ.

PLoS One. 2012;7(7):e41144. doi: 10.1371/journal.pone.0041144. Epub 2012 Jul 19.

19.

Basic research in HIV vaccinology is hampered by reductionist thinking.

Van Regenmortel MH.

Front Immunol. 2012 Jul 9;3:194. doi: 10.3389/fimmu.2012.00194. eCollection 2012.

20.

Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120.

West AP Jr, Diskin R, Nussenzweig MC, Bjorkman PJ.

Proc Natl Acad Sci U S A. 2012 Jul 24;109(30):E2083-90. doi: 10.1073/pnas.1208984109. Epub 2012 Jun 27.

Supplemental Content

Support Center